news

CUPERTINO, Calif., Jan 03, 2007 /PRNewswire-FirstCall via COMTEX News Network/ — DURECT Corporation (Nasdaq: DRRX) today announced that we have started Phase II dosing in the U.S. under an FDA-accepted Investigational New Drug (IND) application for TRANSDUR(TM)-Bupivacaine (DUR-843), a transdermal pain patch for patients suffering from Post-Herpetic Neuralgia (post-shingles pain or PHN). DURECT’s Phase I […]

CUPERTINO, Calif., Dec. 18 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today announced that Terrence F. Blaschke, M.D. has joined its Board of Directors. Dr. Blaschke has served on the faculty of Stanford University for over 30 years and is Professor of Medicine and Molecular Pharmacology (Active Emeritus) at the Stanford University School of Medicine. During

CUPERTINO, Calif., Dec. 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has successfully completed Phase I clinical trials with a new product, DUR-843, which is intended to treat a persistent pain condition. We believe that the persistent pain market remains underserved and that DUR-843 has the potential to provide several advantages over

CUPERTINO, Calif., Nov. 30 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today reported positive results from a Phase I clinical trial evaluating an abuse-resistant opioid pain drug candidate based on DURECT’s patented ORADUR(TM) technology. The event was announced on November 29 by Pain Therapeutics, Inc., DURECT’s licensee of the rights to this drug candidate. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO

CUPERTINO, Calif., Nov. 29 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today the signing of a collaboration agreement with Nycomed, a privately held European pharmaceutical company headquartered in Denmark, whereby the companies will jointly develop DURECT’s POSIDUR(TM) post-operative pain relief depot. Nycomed will have exclusive commercialization rights in Europe and other select countries, and DURECT

CUPERTINO, Calif., Nov. 3 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2006. Total revenues were $5.1 million for the three months ended September 30, 2006, compared to $8.6 million for the same period in 2005. Net loss for the three months ended September 30, 2006

CUPERTINO, Calif., Oct. 31 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at three upcoming life sciences conferences in New York, NY. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) Susquehanna International Group Emerging Trends Conference on Wednesday, November 1st, 2006 at The Peninsula Hotel at 9:30 a.m. EST. Rodman & Renshaw Healthcare

CUPERTINO, Calif., Oct. 27 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2006 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Friday, November 3rd, 2006 at 8:30 AM EST. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) What: DURECT Corporation’s Third Quarter 2006

CUPERTINO, Calif., Oct. 19 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Voyager Pharmaceutical has informed DURECT that Voyager is ending its Phase III clinical trials for Memryte(TM) for the treatment of Alzheimer’s Disease in order to get an earlier look at potential efficacy from over 600 accrued patients. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) “We look

CUPERTINO, Calif., Oct. 16 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview at the BIO InvestorForum 2006 conference. The conference is being held at The Palace Hotel in San Francisco, CA. Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the conference on Wednesday,